01—Abstract
Summary
Summary of the 10-Q filed April 23, 2025. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson (JNJ) reported a strong first quarter for fiscal year 2025, with worldwide sales reaching $21.9 billiona, a 2.4% increase year-over-year.
This growth was driven by a robust operational increase of 4.2%b, partially offset by a 1.8% negative currency impact. The Innovative Medicine segment showed resilience with a 2.3% sales increase, fueled by strong performance in Oncology, particularly with products like Darzalex and CARVYKTI, despite a significant 33.7% decline in Stelara sales due to biosimilar competition. The MedTech segment also grew by 2.5%, boosted by the recent acquisition of Shockwave Medical and continued strength in Cardiovascular and Vision product lines.
The company reported a substantial increase in net earnings to $11.0 billionc from $3.3 billion in the prior year's quarter. This significant jump was largely influenced by the reversal of approximately $7.0 billion related to the previously accrued talc reserve, which had a material positive impact on the 'Other (income) expense, net' line item. Excluding this one-time item, operational performance remains solid, demonstrating the company's ongoing ability to drive growth across its diverse portfolio.
02—Key points
Key Highlights
- Worldwide sales increased by 2.4% to $21.9 billion, driven by a 4.2% operational increase.
- Innovative Medicine segment sales grew 2.3% to $13.9 billion, with Oncology being a key growth driver.
- MedTech segment sales increased 2.5% to $8.0 billion, bolstered by the Shockwave Medical acquisition.
- Net earnings surged to $11.0 billion, significantly impacted by the reversal of a $7.0 billion talc reserve.
- The company completed a significant $9.2 billion issuance of senior unsecured notes to fund the acquisition of Intra-Cellular Therapies, Inc.
- Despite strong overall growth, Stelara sales saw a significant 33.7% decline due to biosimilar competition.
- Earnings per share (EPS) increased significantly to $4.54 (diluted) from $1.34 in the prior year's quarter.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 23, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $21.89B$21.38B | +2.4% |
| Cost of Revenue | $7.36B$6.51B | +13.0% |
| Gross Profit | $14.54B$14.87B | −2.3% |
| SG&A Expenses | $5.11B$5.26B | −2.8% |
| Net Income | $11.00B$3.25B | +237.9% |
| EPS (Basic) | $4.57$1.35 | +238.5% |
| EPS (Diluted) | $4.54$1.34 | +238.8% |
| Shares Outstanding (Basic) | 2.41B2.41B | 0.0% |
| Shares Outstanding (Diluted) | 2.42B2.43B | −0.3% |
05—Questions
Frequently Asked Questions
What was the primary driver for the significant increase in net earnings this quarter?
The primary driver for the substantial increase in net earnings to $11.0 billion was the reversal of approximately $7.0 billion related to the previously accrued talc reserve. This one-time item significantly boosted the 'Other (income) expense, net' category.
How is the company managing the impact of biosimilar competition on Stelara sales?
Stelara sales experienced a significant 33.7% decline due to biosimilar competition. Johnson & Johnson anticipates continued launches of biosimilar versions of Stelara in 2025, which will impact future sales of the product. The company is focusing on growth drivers in other areas of its portfolio to offset these declines.
What is the impact of recent acquisitions on the company's financial performance?
The company completed the acquisition of Shockwave Medical in the MedTech segment, which contributed to the segment's 2.5% sales growth. Additionally, subsequent to the quarter, J&J acquired Intra-Cellular Therapies, Inc. for approximately $14.6 billion, funded by cash and debt issuance, which is expected to contribute to the Innovative Medicine segment.
What is the company's outlook regarding its ongoing legal proceedings, particularly concerning talc and opioids?
The company continues to address its legal liabilities. While the talc bankruptcy case was dismissed, leading to a reversal of a significant portion of the reserve, the company still has approximately $4.2 billion reserved for talc matters. For opioid litigation, approximately 70% of the $5.0 billion settlement has been paid, with an estimated $1.5 billion remaining to settle these claims. The company believes it has sufficient liquidity to manage these obligations.
06—Continue